Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
OBJECTIVE
To test the hypothesis that the concentration of early follicular phase serum antimullerian hormone (AMH) or mullerian-inhibiting substance (MIS) is a useful marker of ovarian response and assisted reproductive technology (ART) outcome.


METHODS
Retrospective analysis of day 3 serum samples drawn before treatment.


METHODS
Private ART program.


METHODS
One hundred nine consecutive serum samples from women younger than 42 years of age who were undergoing ovulation induction for IVF.


METHODS
Follicular aspiration for IVF after ovarian stimulation with FSH in a down-regulated cycle using GnRH-a treatment.


METHODS
Correlations between day 3 serum AMH/MIS, E2, FSH, inhibin B levels, and IVF outcome (i.e., number of retrieved mature oocytes, number and quality of embryos obtained, ongoing clinical pregnancy rates). Multivariate regression analysis on categorical data was performed to describe a predictive model of clinical pregnancy outcome.


RESULTS
Mean serum AMH/MIS value for clinical pregnancy (n = 38) was 2.4 ng/mL, in comparison to 1.1 ng/mL for those who did not become pregnant (n = 71). No differences were noted in mean values for day 3 FSH, inhibin B, or E2 between groups. Multivariate regression analysis demonstrated that day 3 serum AMH/MIS had the greatest independent contribution in predicting pregnancy outcomes.


CONCLUSIONS
These data demonstrate a strong association between day 3 serum AMH/MIS level and IVF outcome in women younger than 42 years of age. Higher AMH/MIS concentrations are associated with a greater number of mature oocytes, a greater number of embryos, and ultimately a higher clinical pregnancy rate. Furthermore, AMH/MIS may offer greater prognostic value than other currently available serum markers of ART outcome.
Hazout
André
A
ART Unit Eylau la Muette, Clinic La Muette, Paris, France. ahazout@hotmail.com
Bouchard
Philippe
P
Seifer
David B
DB
Aussage
P
P
Junca
Anne Marie
AM
Cohen-Bacrie
Paul
P
D000328:Adult; D054304:Anti-Mullerian Hormone; D015415:Biomarkers / Q000097:blood; D004958:Estradiol / Q000097:blood*; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D007265:Inhibins / Q000097:blood*; D015999:Multivariate Analysis; D009994:Osmolar Concentration; D010062:Ovulation Induction; D011237:Predictive Value of Tests; D011247:Pregnancy; D018873:Pregnancy Rate; D012189:Retrospective Studies; D013735:Testicular Hormones / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D006023:Glycoproteins; D013735:Testicular Hormones; C422364:inhibin B; D004958:Estradiol; D007265:Inhibins; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone